Sugi Predict

Sugi Predict / Compounds / SCHEMBL7188977

SCHEMBL7188977

SCHEMBL7188977

COc1cc(OC)c(C(=O)c2ccccc2[P](=O)C(=O)c2c(OC)cccc2OC)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.41
▸ ABCG2 Q9UNQ0 3/20 0.41
▸ AURKA O14965 1/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ CYP3A4 P08684 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ TP53 P04637 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ ATM Q13315 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ KCNK3 O14649 1/20 0.38
▸ KCNK9 Q9NPC2 1/20 0.38
▸ MAOA P21397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7732147 0.91 MAPT (0.44) MAPTABCG2SMN1; SMN2MAPK1TP53
SCHEMBL7180294 0.90 ALDH1A1 (0.43) MAPTABCG2CYP3A4SMN1; SMN2USP2
SCHEMBL7736110 0.90 ALDH1A1 (0.43) MAPTABCG2CYP3A4SMN1; SMN2USP2
SCHEMBL7182106 0.89 KMT2A (0.45) MAPTABCG2CYP3A4SMN1; SMN2USP2
SCHEMBL7188172 0.89 SMN1; SMN2 (0.38) MAPTABCG2CYP3A4SMN1; SMN2USP2
SCHEMBL7175462 0.89 KMT2A (0.45) MAPTABCG2CYP3A4SMN1; SMN2USP2
SCHEMBL7185481 0.89 NPC1 (0.40) MAPTABCG2CYP3A4SMN1; SMN2USP2
SCHEMBL7181292 0.89 ALDH1A1 (0.38) MAPTABCG2CYP3A4SMN1; SMN2USP2
SCHEMBL7177204 0.88 PKM (0.38) MAPTABCG2CYP3A4SMN1; SMN2USP2
SCHEMBL7182505 0.88 KMT2A (0.40) MAPTABCG2CYP3A4SMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885ABCG2 3732/4885AURKA 2167/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885ABCG2 4323/4885AURKA 2395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.